医学临床研究
  2025年4月8日 星期二           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (10): 1547-1549    DOI: 10.3969/j.issn.1671-7171.2021.10.030
  论著 本期目录 | 过刊浏览 | 高级检索 |
黄芪甲苷调控p38 MAPK信号通路治疗小鼠肾小管间质纤维化的实验研究
周淑娟, 李伟*
陕西省延安市人民医院肾内科,陕西 延安 716000
Experimental Study of Astragaloside IV Regulating p38 MAPK Signaling Pathway in the Treatment of Renal Tubulointerstitial Fibrosis
ZHOU Shu-juan, LI Wei
Department of Nephrology, Yan'an people's Hospital, Shaanxi Province,Yan'an 716000
全文: PDF (1675 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨黄芪甲苷(AS-Ⅳ)调控p38丝裂原活化蛋白激酶(MAPK)通路对肾小管间质纤维化的改善作用。【方法】在C57BL/6小鼠中建立单侧输尿管结扎(UUO)致肾小管间质纤维化动物模型,分为假手术组(A组)、模型组(B组)和治疗组(C组)。C组连续7 d予以20 mg/(kg·d) AS-Ⅳ灌胃,A组和B组予以同等剂量的生理盐水灌胃。2周后取手术侧肾组织观察肾脏病理改变(Masson染色),实时定量PCR检测转化生长因子-β1(TGF-β1) mRNA表达。将NRK-49F细胞根据体外细胞培养基不同分为:阴性对照组、TGF-β1组(加TGF-β1 10 ng/mL刺激细胞)、TGF-β1+AS-Ⅳ组(TGF-β1刺激前,分别添加剂量50、100、200 μg/mL AS-Ⅳ处理1h),观察NRK-49F细胞内p-p38蛋白水平(Western法)。【结果】A、B、C组肾组织TGF-β1 mRNA相对表达分别为2.65±0.38,28.71±4.05和20.29±3.10, A组在较低水平;与A组相比,B、C组肾组织TGF-β1 mRNA表达较A组明显增加(P<0.01),C组表达明显低于B组(P<0.05)。体外试验结果提示:p-p38蛋白水平,TGF-β1组>阴性对照组(P<0.01),TGF-β1组>TGF-β1+AS-Ⅳ组(P<0.01),TGF-β1+AS-Ⅳ组中不同剂量各组比较差异均有显著性(P<0.01)。【结论】AS-Ⅳ可以下调TGF-β1表达水平,减轻肾小管间质纤维化,其保护作用可能与AS-Ⅳ抑制p38 MAPK的磷酸化有关。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
周淑娟
李伟
关键词 肾疾病/病理学小鼠肾炎间质性/病理学黄芪甙信号传导    
Abstract:【Objective】To investigate the effect of astragaloside Ⅳ(AS-Ⅳ) regulating p38 mitogen activated protein kinase (MAPK) pathway on renal tubulointerstitial fibrosis.【Methods】 The animal model of tubulointerstitial fibrosis induced by unilateral ureteral ligation (UUO) was established in C57BL/6 mice and divided into sham operation group (group A), model group (group B) and treatment group (Group C). Group C was gavaged with 20 mg/(kg·d) as-iv for 7 days, and group A and B were gavaged with the same dose of physiological salt water. After 2 weeks, the pathological changes of the kidney were observed (Masson staining), and the transforming growth factor was detected by real-time quantitative TGF-β1 mRNA expression by PCR. According to different cell culture media, NRK-49F cells were divided into negative control group ,TGF-β1 Group (with TGF-β1 10 ng/mL stimulated cells), TGF-β1 + AS-Ⅳ group (before TGF-β1 stimulation, add doses of 50, 100 and 200 μg/mL AS-Ⅳ treatment for 1 h respectively), and the level of p-p38 protein in NRK-49F cells was observed (Western method).【Results】 The relative expression of TGF-β1 mRNA in renal tissue of group A , B and C was 2.65±0.38, 28.71±4.05 and 20.29±3.10, and the group A was at a lower level. Compared with the group A, the renal TGF -β1 mRNA expression in the group B and C was significantly higher than that in the group A (P<0.01), the expression in the group C was significantly lower than that in the group B(P<0.05). The results of in vitro test showed that p-p38 protein level, TGF-β1 GrouP>negative control group (P<0.01), TGF-β1 GrouP>TGF-β1 + AS-Ⅳ group (P<0.01), TGF-β1 + AS-Ⅳ group 200 μg/mL< 100 μg/mL<50 μg/mL(P<0.01). 【Conclusion】AS-Ⅳ can reduce TGF-β1 level, reduce renal tubulointerstitial fibrosis, and its protective effect may be related to the inhibition of p38 MAPK phosphorylation by AS-Ⅳ.
Key wordsKidney Diseases/PA    Mice    Nephritis, Interstitial/PA    ASTRAGALIN    Signal Transduction
收稿日期: 2020-10-27     
中图分类号:  R693.2  
通讯作者: *E-mail:125740648@qq.com.   
引用本文:   
周淑娟, 李伟. 黄芪甲苷调控p38 MAPK信号通路治疗小鼠肾小管间质纤维化的实验研究[J]. 医学临床研究, 2021, 38(10): 1547-1549.
ZHOU Shu-juan, LI Wei. Experimental Study of Astragaloside IV Regulating p38 MAPK Signaling Pathway in the Treatment of Renal Tubulointerstitial Fibrosis. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1547-1549.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.10.030     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I10/1547
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn